Why the study?
Ponatinib represents an effective option for patients with CML with sequential treatment resistance, but it has been associated with cardiovascular events, necessitating recommendations for cardiovascular risk management.
A multidisciplinary Delphi analysis provides clinical practice recommendations to optimize cardiovascular risk control in CML patients requiring ponatinib treatment.
Answers are grounded in this paper and cite their sources.
Ponatinib use in resistant CML warrants close CV monitoring; Level 5 data leaves optimal mitigation strategies open.
Progress in the treatment of Chronic Myeloid Leukaemia (CML) has significantly improved the survival rates and prognosis of these patients. As a result, there is a growing awareness of the adverse effects that the treatments used can have on the Cardiovascular (CV) system. A high percentage of patients develop sequential resistance to CML treatments and, in these cases, ponatinib represents a good therapeutic option that has been associated with cardiovascular events. This required the development of recommendations for its management. A Delphi analysis conducted by a multidisciplinary panel of experts developed and agreed on clinical practice recommendations to optimize cardiovascular risk control in CML patients requiring ponatinib treatment.
No takes yet. Share an insight, caveat, or question.
Jl et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: